Tomas N.
- Country
- Czechia
- Department
- N/A
Research Overview
- Long-Term Safety and Tolerability of Atogepant for Migraine Prevention in Chronic or Episodic Migraine: A Phase 3, 156-Week Extension Study
- Efficacy and Safety Evaluation of Botulinum Toxin Type A in Chronic Migraine Prevention in Adults: A Randomized, Double-Blind, Placebo-Controlled Study
- Efficacy and Safety Evaluation of Botulinum Toxin Type A in Preventing Episodic Migraine in Adults: A Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 95 of 244 partner sites.
Specializations
Major Depressive Disorder and Treatment-Resistant Depression
The investigator is involved in clinical research focused on major depressive disorder, including treatment-resistant depression, anhedonia, and depression with or without anxious distress. This area also includes adjunctive and monotherapy approaches aimed at improving depressive symptoms and relapse prevention.
- Major depressive disorder
- Treatment-resistant depression
- Anhedonia
- Relapse prevention in depression
- Depression with anxious distress
Therapeutic interest extends across novel antidepressant strategies and long-term management of persistent mood symptoms.
Migraine and Headache Prevention
His research landscape includes migraine care, with attention to both episodic migraine and chronic migraine, as well as acute treatment and prevention of recurrent headache burden. The work also covers migraine populations with different clinical patterns and preventive needs.
- Episodic migraine
- Chronic migraine
- Acute migraine treatment
- Migraine prevention
- Recurrent headache disorders
This therapeutic focus supports innovation in preventive and symptom-targeted migraine management.
Alzheimer’s Disease and Related Neuropsychiatric Symptoms
The investigator is active in studies centered on Alzheimer’s disease, particularly agitation, psychosis, and cognitive impairment associated with the disorder. The research scope also includes mild-to-moderate and early-stage disease presentations.
- Alzheimer’s disease
- Agitation associated with Alzheimer’s disease
- Alzheimer’s disease psychosis
- Cognitive impairment in Alzheimer’s disease
- Early Alzheimer’s disease
Therapeutic emphasis is placed on neuropsychiatric symptom control and cognitive preservation in dementia-related conditions.
Schizophrenia and Cognitive Disorders
His clinical trial activity includes schizophrenia and related cognitive disorders, with interest in psychosis, cognitive impairment associated with schizophrenia, and persistent functional symptoms. This area also encompasses safety-focused research in schizophrenia populations.
- Schizophrenia
- Psychosis
- Cognitive impairment associated with schizophrenia
- Functional impairment
- Safety in schizophrenia
The therapeutic domain reflects attention to symptom burden and cognition in severe mental illness.
Generalized Anxiety Disorder, Tardive Dyskinesia, and Epilepsy
The investigator also contributes to research in generalized anxiety disorder, tardive dyskinesia, and refractory partial onset epilepsy. These studies broaden the clinical portfolio across anxiety, movement disorders, and drug-resistant seizure disorders.
- Generalized anxiety disorder
- Tardive dyskinesia
- Refractory partial onset epilepsy
- Drug-resistant focal onset seizures
- Chronic non-specific low back pain
His therapeutic interests span neuropsychiatric and neurologic conditions with unmet treatment needs.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.